<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02935595</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-16-0705</org_study_id>
    <nct_id>NCT02935595</nct_id>
  </id_info>
  <brief_title>Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients</brief_title>
  <acronym>ketamine</acronym>
  <official_title>A Systematic Investigation of Neurophysiological Correlates of Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of the project is to study the effect of Ketamine on cortical&#xD;
      neurophysiological function in TRD patients. The proposal employs robust and non-invasive&#xD;
      neurophysiological techniques TMS and EEG to investigate the cortical excitability and&#xD;
      oscillatory activity in patients with treatment resistant depression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal of the project is to study the effect of Ketamine on cortical&#xD;
      neurophysiological function in Treatment Resistant Depression(TRD) patients. There are three&#xD;
      key preclinical findings regarding Ketamine antidepressant effects that motivate the current&#xD;
      study: a) low dose Ketamine causes early increase in glutamate neurotransmission; b) Ketamine&#xD;
      initiates synaptic plasticity; c) ketamine infusion leads to rapid improvement in depression&#xD;
      symptoms. The proposal essentially employs robust and non-invasive neurophysiological&#xD;
      techniques, Auditory Steady State Response(ASSR)-gamma oscillatory response and Transcranial&#xD;
      Magnetic Stimulation(TMS) cortical excitability to investigate the above findings in patients&#xD;
      with treatment resistant depression.&#xD;
&#xD;
      Study:&#xD;
&#xD;
      Ketamine Infusion:&#xD;
&#xD;
      We will employ an open-label study in which the infusion session, the enrolled TRD patients&#xD;
      will receive low dose Ketamine (0.5 mg/kg) over 40 minutes.&#xD;
&#xD;
      Cortical Excitability:&#xD;
&#xD;
      TMS stimulation will be applied to the corresponding region of the contralateral primary&#xD;
      motor cortex to determine motor threshold and to examine the motor cortical excitability&#xD;
      measures after Ketamine. The optimal coil position will be determined by moving the TMS coil&#xD;
      in 1-cm increments over the motor cortical area while delivering single or paired magnetic&#xD;
      pulses and by observing maximal contraction of the contralateral abductor pollicis brevis&#xD;
      (APB). Electromyography readings will be obtained from the APB muscle. TMS stimulation will&#xD;
      then be applied to Left DLPFC or Left Brodmann Area 6 to investigate cortical excitability&#xD;
      changes after ketamine. Electroencephalography(EEG) recordings will be concurrent with TMS&#xD;
      procedure.&#xD;
&#xD;
      ASSR/EEG paradigm:&#xD;
&#xD;
      Participants may engage in the auditory steady state response task where click trains of&#xD;
      500-ms duration will be presented binaurally at 65 ± 5 decibel(dB). The click train&#xD;
      repetition frequencies will be 40 Hz and presented in the context of an auditory oddball&#xD;
      paradigm to ensure participant attention to the stimuli. This task will be done while&#xD;
      participants undergo EEG recordings.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 14, 2016</start_date>
  <completion_date type="Actual">August 16, 2017</completion_date>
  <primary_completion_date type="Actual">August 16, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cortical Excitability in the Dorsolateral Prefrontal Cortex (DLPFC) as Assessed by Transcranial Magnetic Stimulation-evoked Activity Detected by Electroencephalography (TMS-EEG)</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cortical Excitability in DLPFC Using TMS-EEG</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cortical Excitability in DLPFC Using TMS-EEG</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cortical Excitability in DLPFC Using TMS-EEG</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of Depressive Symptoms as Assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Baseline</time_frame>
    <description>Total MADRS score ranges from 0 to 60, and a higher score indicates more severe depression, as follows:&#xD;
0 to 6 - normal/symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression &gt;34 - severe depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Depressive Symptoms as Assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>4 hours</time_frame>
    <description>Total MADRS score ranges from 0 to 60, and a higher score indicates more severe depression, as follows:&#xD;
0 to 6 - normal/symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression &gt;34 - severe depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Depressive Symptoms as Assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>24 hours</time_frame>
    <description>Total MADRS score ranges from 0 to 60, and a higher score indicates more severe depression, as follows:&#xD;
0 to 6 - normal/symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression &gt;34 - severe depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as Indicated by Number of Adverse Events</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Slow infusions of ketamine will take place over a time period of 40 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine Hydrochloride Injection</description>
    <arm_group_label>Ketamine</arm_group_label>
    <other_name>Ketamine Hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be between 18-60 years of age&#xD;
&#xD;
          -  Meet criteria for Treatment Resistant Depression (defined as two or more unsuccessful&#xD;
             trials of antidepressants at an adequate dose for at least 4 weeks)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with intellectual disability, eg. Mental retardation, neurodegenerative&#xD;
             diseases, eg. Early onset neurocognitive disturbances such as frontotemporal dementia&#xD;
             or behavioral disorders, eg. adult onset Attention Deficit Hyperactivity Disorder,&#xD;
&#xD;
          -  Diagnosed with Bipolar Disorder (BD),&#xD;
&#xD;
          -  Diagnosed with personality disorders,&#xD;
&#xD;
          -  Previously or currently diagnosed with psychosis (schizoaffective disorder -SAD) or&#xD;
             schizophrenia - SCZ),&#xD;
&#xD;
          -  Current major medical problems that affect brain anatomy, neurochemistry, or function,&#xD;
             e.g., obstructive sleep apnea requiring Continuous Positive Airway Pressure (CPAP),&#xD;
             liver insufficiency, kidney insufficiency, cardiovascular problems, systemic&#xD;
             infections, cancer, auto-immune diseases, and any brain disorder (seizure disorder,&#xD;
             stroke, dementia, degenerative neurologic diseases); history of any brain diseases,&#xD;
             including seizures, stroke, meningitis, encephalitis, dementia, degenerative brain&#xD;
             diseases, and head injury with loss of consciousness for any period of time,&#xD;
&#xD;
          -  Diagnosed specifically with a cardiovascular disorders such as Hypertension,&#xD;
             Arrhythmias, Chronic Heart Failure, Myocardial Infarction (MI) or suffering from&#xD;
             Chronic Obstructive Pulmonary Disease (COPD) or asthma. Cardiac clearance prior to&#xD;
             enrolling in the study and medical records from physician will be required per&#xD;
             patient's Primary Care Physician.&#xD;
&#xD;
          -  Patients with increased risk of laryngospasm, active upper respiratory infections,&#xD;
             respiratory depression, increased intracranial pressure, thyroid disease, or&#xD;
             porphyria,&#xD;
&#xD;
          -  Current substance abuse or dependence. Only patients who achieved stable, full&#xD;
             remission for at least 6 months will be included&#xD;
&#xD;
          -  Pregnancy or Breast feeding. All female in reproductive age will undergo pregnancy&#xD;
             tests. Female participants will be required to provide evidence of use of&#xD;
             contraceptives during the course of the study,&#xD;
&#xD;
          -  Unable to understand the design and requirements of the study.&#xD;
&#xD;
          -  Unable to sign the informed consent for any reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudhakar Selvaraj, MBBS, DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harris County Psychiatric Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 12, 2016</study_first_submitted>
  <study_first_submitted_qc>October 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2016</study_first_posted>
  <results_first_submitted>August 13, 2020</results_first_submitted>
  <results_first_submitted_qc>August 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 31, 2020</results_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Sudhakar Selvaraj</investigator_full_name>
    <investigator_title>MBBS., DPhil (Oxon)., MRCPsych</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 2, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT02935595/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>3 subjects signed consent and were screened, but met exclusion criteria and were thus excluded from the study before starting.&#xD;
1 subject withdrew consent after screening and did not start the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ketamine</title>
          <description>Slow infusions of ketamine will take place over a time period of 40 minutes.&#xD;
Ketamine: Ketamine Hydrochloride Injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine</title>
          <description>Slow infusions of ketamine will take place over a time period of 40 minutes.&#xD;
Ketamine: Ketamine Hydrochloride Injection</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.20" spread="10.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>Race data was not collected from 1 participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cortical Excitability in the Dorsolateral Prefrontal Cortex (DLPFC) as Assessed by Transcranial Magnetic Stimulation-evoked Activity Detected by Electroencephalography (TMS-EEG)</title>
        <time_frame>Baseline</time_frame>
        <population>Data was not collected for one participant.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Slow infusions of ketamine will take place over a time period of 40 minutes.&#xD;
Ketamine: Ketamine Hydrochloride Injection</description>
          </group>
        </group_list>
        <measure>
          <title>Cortical Excitability in the Dorsolateral Prefrontal Cortex (DLPFC) as Assessed by Transcranial Magnetic Stimulation-evoked Activity Detected by Electroencephalography (TMS-EEG)</title>
          <population>Data was not collected for one participant.</population>
          <units>microvolt milliseconds (µV ms)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="446.08" spread="209.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cortical Excitability in DLPFC Using TMS-EEG</title>
        <time_frame>4 hours</time_frame>
        <population>Data was not collected for 1 participant.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Slow infusions of ketamine will take place over a time period of 40 minutes.&#xD;
Ketamine: Ketamine Hydrochloride Injection</description>
          </group>
        </group_list>
        <measure>
          <title>Cortical Excitability in DLPFC Using TMS-EEG</title>
          <population>Data was not collected for 1 participant.</population>
          <units>microvolt milliseconds (µV ms)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="319.71" spread="206.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cortical Excitability in DLPFC Using TMS-EEG</title>
        <time_frame>24 hours</time_frame>
        <population>Data was not collected for 1 participant.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Slow infusions of ketamine will take place over a time period of 40 minutes.&#xD;
Ketamine: Ketamine Hydrochloride Injection</description>
          </group>
        </group_list>
        <measure>
          <title>Cortical Excitability in DLPFC Using TMS-EEG</title>
          <population>Data was not collected for 1 participant.</population>
          <units>microvolt milliseconds (µV ms)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330.30" spread="222.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cortical Excitability in DLPFC Using TMS-EEG</title>
        <time_frame>7 days</time_frame>
        <population>Data was not collected from any participant at 7 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Slow infusions of ketamine will take place over a time period of 40 minutes.&#xD;
Ketamine: Ketamine Hydrochloride Injection</description>
          </group>
        </group_list>
        <measure>
          <title>Cortical Excitability in DLPFC Using TMS-EEG</title>
          <population>Data was not collected from any participant at 7 days.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Depressive Symptoms as Assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)</title>
        <description>Total MADRS score ranges from 0 to 60, and a higher score indicates more severe depression, as follows:&#xD;
0 to 6 - normal/symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression &gt;34 - severe depression</description>
        <time_frame>Baseline</time_frame>
        <population>Data was not collected for one participant.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Slow infusions of ketamine will take place over a time period of 40 minutes.&#xD;
Ketamine: Ketamine Hydrochloride Injection</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Depressive Symptoms as Assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)</title>
          <description>Total MADRS score ranges from 0 to 60, and a higher score indicates more severe depression, as follows:&#xD;
0 to 6 - normal/symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression &gt;34 - severe depression</description>
          <population>Data was not collected for one participant.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.50" spread="7.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Depressive Symptoms as Assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)</title>
        <description>Total MADRS score ranges from 0 to 60, and a higher score indicates more severe depression, as follows:&#xD;
0 to 6 - normal/symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression &gt;34 - severe depression</description>
        <time_frame>4 hours</time_frame>
        <population>Data was not collected for one participant.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Slow infusions of ketamine will take place over a time period of 40 minutes.&#xD;
Ketamine: Ketamine Hydrochloride Injection</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Depressive Symptoms as Assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)</title>
          <description>Total MADRS score ranges from 0 to 60, and a higher score indicates more severe depression, as follows:&#xD;
0 to 6 - normal/symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression &gt;34 - severe depression</description>
          <population>Data was not collected for one participant.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" spread="9.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Depressive Symptoms as Assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)</title>
        <description>Total MADRS score ranges from 0 to 60, and a higher score indicates more severe depression, as follows:&#xD;
0 to 6 - normal/symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression &gt;34 - severe depression</description>
        <time_frame>24 hours</time_frame>
        <population>Data was not collected for one participant.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Slow infusions of ketamine will take place over a time period of 40 minutes.&#xD;
Ketamine: Ketamine Hydrochloride Injection</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Depressive Symptoms as Assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)</title>
          <description>Total MADRS score ranges from 0 to 60, and a higher score indicates more severe depression, as follows:&#xD;
0 to 6 - normal/symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression &gt;34 - severe depression</description>
          <population>Data was not collected for one participant.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.25" spread="7.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety as Indicated by Number of Adverse Events</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Slow infusions of ketamine will take place over a time period of 40 minutes.&#xD;
Ketamine: Ketamine Hydrochloride Injection</description>
          </group>
        </group_list>
        <measure>
          <title>Safety as Indicated by Number of Adverse Events</title>
          <units>Number of adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ketamine</title>
          <description>Slow infusions of ketamine will take place over a time period of 40 minutes.&#xD;
Ketamine: Ketamine Hydrochloride Injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depersonalization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sudhakar Selvaraj, MD, PhD, Assistant Professor</name_or_title>
      <organization>The University of Texas Health Science Center at Houston</organization>
      <phone>(713) 486-2500</phone>
      <email>Sudhakar.Selvaraj@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

